These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9478921)

  • 21. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
    Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin receptor-mediated p62dok tyrosine phosphorylation at residues 362 and 398 plays distinct roles for binding GTPase-activating protein and Nck and is essential for inhibiting insulin-stimulated activation of Ras and Akt.
    Wick MJ; Dong LQ; Hu D; Langlais P; Liu F
    J Biol Chem; 2001 Nov; 276(46):42843-50. PubMed ID: 11551902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downstream of kinase, p62(dok), is a mediator of Fc gamma IIB inhibition of Fc epsilon RI signaling.
    Ott VL; Tamir I; Niki M; Pandolfi PP; Cambier JC
    J Immunol; 2002 May; 168(9):4430-9. PubMed ID: 11970986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tyrosine phosphorylation of p62(Dok) induced by cell adhesion and insulin: possible role in cell migration.
    Noguchi T; Matozaki T; Inagaki K; Tsuda M; Fukunaga K; Kitamura Y; Kitamura T; Shii K; Yamanashi Y; Kasuga M
    EMBO J; 1999 Apr; 18(7):1748-60. PubMed ID: 10202139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.
    Nichols GL; Raines MA; Vera JC; Lacomis L; Tempst P; Golde DW
    Blood; 1994 Nov; 84(9):2912-8. PubMed ID: 7524758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST
    Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyrosine phosphorylation of murine Crkl.
    de Jong R; Haataja L; Voncken JW; Heisterkamp N; Groffen J
    Oncogene; 1995 Oct; 11(8):1469-74. PubMed ID: 7478571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphatidylinositol 3-kinase and Src family kinases are required for phosphorylation and membrane recruitment of Dok-1 in c-Kit signaling.
    Liang X; Wisniewski D; Strife A; Shivakrupa ; Clarkson B; Resh MD
    J Biol Chem; 2002 Apr; 277(16):13732-8. PubMed ID: 11825908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tyrosine phosphorylated proteins in chronic myelogenous leukemia.
    Frackelton AR; Kumar PS; Kannan B; Clark JW
    Leuk Lymphoma; 1993; 11 Suppl 1():125-9. PubMed ID: 7504542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
    Campbell ML; Li W; Arlinghaus RB
    Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The phosphatidylinositol polyphosphate 5-phosphatase SHIP1 associates with the dok1 phosphoprotein in bcr-Abl transformed cells.
    Dunant NM; Wisniewski D; Strife A; Clarkson B; Resh MD
    Cell Signal; 2000 May; 12(5):317-26. PubMed ID: 10822173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia.
    Wisniewski D; Strife A; Berman E; Clarkson B
    Leukemia; 1996 Feb; 10(2):229-37. PubMed ID: 8637231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stromal cell-derived factor-1alpha/CXCL12-induced chemotaxis of T cells involves activation of the RasGAP-associated docking protein p62Dok-1.
    Okabe S; Fukuda S; Kim YJ; Niki M; Pelus LM; Ohyashiki K; Pandolfi PP; Broxmeyer HE
    Blood; 2005 Jan; 105(2):474-80. PubMed ID: 15345598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganization.
    Master Z; Tran J; Bishnoi A; Chen SH; Ebos JM; Van Slyke P; Kerbel RS; Dumont DJ
    J Biol Chem; 2003 Aug; 278(32):30170-9. PubMed ID: 12777393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dok-1 tyrosine residues at 336 and 340 are essential for the negative regulation of Ras-Erk signalling, but dispensable for rasGAP-binding.
    Shinohara H; Yasuda T; Yamanashi Y
    Genes Cells; 2004 Jun; 9(6):601-7. PubMed ID: 15189452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The roles of Dok family adapters in immunoreceptor signaling.
    Mashima R; Hishida Y; Tezuka T; Yamanashi Y
    Immunol Rev; 2009 Nov; 232(1):273-85. PubMed ID: 19909370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
    Puil L; Liu J; Gish G; Mbamalu G; Bowtell D; Pelicci PG; Arlinghaus R; Pawson T
    EMBO J; 1994 Feb; 13(4):764-73. PubMed ID: 8112292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ubiquitin-mediated interaction of p210 BCR/ABL with β-catenin supports disease progression in a murine model for chronic myelogenous leukemia.
    Chen R; Hu T; Mahon GM; Tala I; Pannucci NL; Ozer HL; Whitehead IP
    Blood; 2013 Sep; 122(12):2114-24. PubMed ID: 23950177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells.
    Salgia R; Uemura N; Okuda K; Li JL; Pisick E; Sattler M; de Jong R; Druker B; Heisterkamp N; Chen LB
    J Biol Chem; 1995 Dec; 270(49):29145-50. PubMed ID: 7493940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.